DOVE
Research type
Research Study
Full title
A three-arm randomized phase II study of Dostarlimab alone or with Bevacizumab versus nonplatinum chemotherapy in recurrent gynecological clear cell carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 study)
IRAS ID
1008886
Contact name
Katie Wilkinson
Contact email
Sponsor organisation
Severance Hospital, Yonsei health System
Clinicaltrials.gov Identifier
Research summary
DOVE is a gynaecological cancer study using two drugs, called Dostarlimab and Bevacizumab. The UK target accrual is 20 (198 Globally) and the study will be run at 1 hospital. Eligible participants will have gynaecological clear cell cancer (GCCC), have received at least one previous treatment for their disease, and whose disease has come back (recurrent). GCCC is a rare type of cancer and the usual treatment is non-platinum chemotherapy. However, this type of cancer doesn't usually respond well to chemotherapy meaning there are fewer treatment options available. This study aims to investigate whether giving Dostarlimab alone, or together with Bevacizumab, can work better than non-platinum chemotherapy.
Women who consent to take part, will be randomised into 1 of 3 groups:
1) ARM A: patients will be given Dostarlimab alone, through intravenous (IV) infusions every 3 weeks for the first 4 courses, then every 6 weeks for up to 2 years.
2) ARM B: patients will be given both Dostarlimab and Bevacizumab together. Dostarlimab treatment will be given as described for ARM A. Bevacizumab will be given through IV infusions every 3 weeks until the cancer starts growing again (progression).
3) ARM C (standard treatment): patients will be given non-platinum chemotherapy until progression. The chemotherapy drug given will be decided by the treating clinician from one of four options: Liposomal Doxorubicin (PLD), Doxorubicin Hydrochloride, Paclitaxel, or Gemcitabine.
The drug may be stopped for the following reasons: if there is an unacceptable side effect, the treating clinician's decision, or if disease becomes worse while taking the study treatment. After end of treatment, patients will be followed up every 6 weeks for 2 years, then every 12 weeks until the disease returns. Blood and biopsy samples will be collected throughout the study.
The study is funded by GlaxoSmithKline, sponsored by Yonsei University, South Korea, and coordinated by CRUK & UCL CTC, UK.REC name
East of England - Cambridge South Research Ethics Committee
REC reference
25/EE/0176
Date of REC Opinion
2 Oct 2025
REC opinion
Further Information Favourable Opinion